市场调查报告书
商品编码
1368726
止血产品市场规模 - 按产品、按应用、按最终用途以及 - 到 2032 年的全球预测Hemostasis Products Market Size - By Product, By Application, By End-use - Global Forecast to 2032 |
由于全球事故和创伤病例发生率不断上升,全球止血产品市场将于 2023 年至 2032 年间以显着的复合年增长率扩张。据国际劳工组织称,全球每年约有 230 万名男性和女性因工伤事故或疾病而丧生,相当于每天有 6,000 多人死亡。每年,全世界都会发生约 3.4 亿起职业事故。止血产品,例如凝血因子和止血剂,对于紧急情况下控制出血至关重要。随着事故和外伤的增加,对这些产品的需求不断上升,因为它们对于拯救生命和防止过度失血至关重要,从而促进了市场的扩张。
整个止血产品市场根据产品、应用、最终用途和地区进行划分。
不输止血产品产业将在 2023-2032 年显着成长。不熔止血产品由于其在各种医疗手术和创伤情况下能够快速控制出血的有效性而受到很高的需求。这些产品,例如凝血因子和止血剂,为最大限度地减少失血、降低併发症风险和改善患者预后提供了关键的解决方案。随着手术、创伤病例和医疗干预数量的增加,对不输止血产品的需求持续增长,推动市场成长。
到2032 年,血友病细分市场可能会累积显着的止血产品市场。由于止血产品在控制这种出血性疾病方面发挥着至关重要的作用,因此越来越多地用于血友病治疗。血友病患者缺乏必需的凝血因子,而止血产品,包括因子浓缩物和凝血因子替代疗法,有助于控制和预防过度出血。随着诊断、治疗和患者护理的改善,血友病治疗中对这些产品的需求不断增加,从而促进了它们在该医疗领域的利用率的提高。
由于多种因素,欧洲止血产品产业正在以显着的速度扩张。该地区人口老化以及需要止血干预的疾病盛行率较高,促进了市场成长。医疗技术和外科手术的进步增加了对这些产品的需求。此外,严格的医疗法规和人们对止血疗法的认识不断提高也促进了止血疗法的使用。这些综合因素为该行业在欧洲的扩张创造了有利的环境。
Global Hemostasis Products Market will expand at a notable CAGR between 2023 and 2032, driven by the growing incidence of accidents and trauma cases across the globe. According to the ILO, approximately 2.3 million men and women globally lose their lives due to work-related accidents or illnesses each year, equating to more than 6,000 daily fatalities. Each year, the world witnesses roughly 340 million occupational accidents. Hemostasis products, such as clotting factors and hemostatic agents, are critical for controlling bleeding in emergencies. With a rise in accidents and traumatic injuries, the demand for these products is on the upswing, as they are essential for saving lives and preventing excessive bleeding, contributing to the market's expansion.
The overall hemostasis products market is segregated based on product, application, end-use, and region.
Infusible hemostasis products industry will register significant growth throughout 2023-2032. Infusible hemostasis products are in high demand due to their effectiveness in rapidly controlling bleeding in various medical procedures and trauma situations. These products, such as clotting factors and hemostatic agents, offer a critical solution for minimizing blood loss, reducing the risk of complications, and improving patient outcomes. With an increasing number of surgeries, trauma cases, and medical interventions, the demand for infusible hemostasis products continues to rise, driving market growth.
The hemophilia segment could accumulate a notable hemostasis products market share by 2032. Hemostasis products are increasingly utilized for hemophilia treatment due to their vital role in managing this bleeding disorder. Hemophilia patients lack essential clotting factors, and hemostasis products, including factor concentrates and clotting factor replacement therapies, help control and prevent excessive bleeding. With improved diagnosis, treatment access, and patient care, the demand for these products in the management of hemophilia is on the rise, contributing to their increased utilization in this medical field.
Europe hemostasis products industry is expanding at a noticeable pace due to several factors. The region's aging population, with a higher prevalence of conditions requiring hemostasis intervention, contributes to market growth. Advances in medical technology and surgical procedures increase the demand for these products. Additionally, stringent healthcare regulations and rising awareness of hemostasis therapies promote their use. These combined factors create a conducive environment for the industry's expansion in Europe.